Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study

The clinical impact of anti-spike monoclonal antibodies (mAb) in Coronavirus Disease 2019 (COVID-19) breakthrough infections is unclear. We present the results of an observational prospective cohort study assessing and comparing COVID-19 progression in high-risk outpatients receiving mAb according t...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoldi, Alessia, Morra, Matteo, Castelli, Alessandro, Mirandola, Massimo, Berkell, Matilda, Smet, Mathias, Konnova, Angelina, Rossi, Elisa, Cataudella, Salvatore, De Nardo, Pasquale, Gentilotti, Elisa, Gupta, Akshita, Fasan, Daniele, Gibbin, Enrico, Cioli Puviani, Filippo, Hasenauer, Jan, Gusinow, Roy, Tami, Adriana, Kumar-Singh, Samir, Malhotra-Kumar, Surbhi, Tacconelli, Evelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495697/
https://www.ncbi.nlm.nih.gov/pubmed/36140162
http://dx.doi.org/10.3390/biomedicines10092063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495697/
https://www.ncbi.nlm.nih.gov/pubmed/36140162
http://dx.doi.org/10.3390/biomedicines10092063

Ejemplares similares